SS-31 (Elamipretide) — The Mitochondrial Restorer
SS-31 (Elamipretide) is a mitochondria-targeted peptide that binds to cardiolipin on the inner mitochondrial membrane, restoring cellular bioenergetics and reducing oxidative stress. While primarily investigated for rare mitochondrial diseases, its ability to rejuvenate mitochondrial function and reverse age-related cardiac and skeletal muscle decline in preclinical models makes it a compelling candidate for longevity research.
Mechanism of Action
Elamipretide (SS-31) is a synthetic, cell-permeable tetrapeptide that selectively targets the inner mitochondrial membrane. It binds to cardiolipin, a unique phospholipid essential for mitochondrial structure and function, stabilizing it and preventing its peroxidation by cytochrome c. This interaction restores the structural assembly of oxidative phosphorylation (OXPHOS) complexes, improves electron transport chain efficiency, and reduces reactive oxygen species (ROS) production. By preserving mitochondrial bioenergetics and ATP production, elamipretide mitigates cellular stress and apoptosis associated with aging and mitochondrial dysfunction.
Human Trial Evidence
Elamipretide has been evaluated in multiple human trials, primarily for primary mitochondrial myopathy and Barth syndrome. A Phase III trial (MMPOWER-3) found that 40 mg/day subcutaneous elamipretide did not significantly improve the 6-minute walk test or fatigue at 24 weeks compared to placebo in primary mitochondrial myopathy (Neurology, 2023). However, long-term open-label extensions suggest potential sustained tolerability and functional improvements in specific populations like Barth syndrome. No published human longevity trials exist.
Dosing Protocol
40 mg/day administered via subcutaneous injection is the standard dose evaluated in clinical trials for primary mitochondrial myopathy. Intravenous infusions up to 0.25 mg/kg/h have also been studied. As an investigational drug, it requires a prescription and clinical supervision.
Safety & Contraindications
Elamipretide is generally well-tolerated in clinical trials, with the most common adverse events being injection site reactions (erythema, pruritus, pain) due to subcutaneous administration. Safety and efficacy for anti-aging purposes have not been established. It should be used with caution or avoided in pregnant or breastfeeding women due to a lack of safety data.